Compare Arqit Quantum Inc (ARQQ) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arqit Quantum Inc vs GSK plc — how do they compare? Arqit Quantum Inc trades at $18.98 (market cap $332.04M), while GSK plc trades at $52.5 (market cap $103.72B). The key difference: GSK plc is far larger — about 312.4× Arqit Quantum Inc's market cap, and GSK plc pays a 3.4% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ARQQ | GSK | |
|---|---|---|
Market Cap | $332.04M | $103.72B |
Sector | Technology | Health |
52-Week High | $58.27 | $61.18 |
52-Week Low | $11.78 | $36.20 |
Enterprise Value | $305.35M | $124.33B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
GSK trades at $52.78, up 0.59% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.27. Revenue grew to $32.67B in 2025, with a net income margin of 17.78%. Recent news includes FDA approval for Utebzi and a $10.6B acquisition of Nuvalent to bolster its oncology pipeline.
GSK presents a balanced outlook with solid profitability and strategic growth in oncology, but faces risks from clinical trial setbacks and competitive pressures. Analyst sentiment is mixed, with 31% buy ratings, suggesting cautious optimism amid pipeline execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
